Oncolytics reports Q4 EPS (10c) vs. (5c) last year

“With multiple clinical trials surpassing expectations in 2024, 2025 is shaping up to be a defining year for Oncolytics (ONCY). Our top priority is HR+/HER2- metastatic breast cancer, in which two randomized trials involving over 100 patients have shown substantial clinical benefit for patients receiving pelareorep and paclitaxel compared to paclitaxel monotherapy,” said Wayne Pisano, Chair of Oncolytics’ Board of Directors and Interim CEO. “We believe that if we can approximate the benefit we saw in BRACELET-1 in our planned registrational study, the progression-free survival benefit alone would support an accelerated approval submission. When adding pancreatic and anal carcinoma to the list of addressable indications where we have generated compelling efficacy signals, pelareorep could have a meaningful impact for a multitude of patients and generate value for our shareholders.” As of December 31, 2024, the company reported $15.9M in cash and cash equivalents. The company has a projected cash runway through key milestones and into the third quarter of 2025.